Institut Mérieux S.A.

https://www.institut-merieux.com

With extensive experience in industrial biology, Institut Mérieux contributes to serving medicine and public health across the globe. For the fight against infectious diseases and cancer, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, and food safety and nutrition. With its three business activities- bioMérieux, Transgene and Silliker-Institut Mérieux has the potential to provide answers to the new challenges of public health globally: personalized medicine and new therapies, infectious diseases and cancer, food safety and nutrition. bioMérieux, listed on NYSE Euronext Paris and 59% owned, is based in Marcy l'Etoile (France). World leader of in vitro diagnostics and industrial microbiological controls. Transgene: Based in Strasburg (France), this biotech company is 55% controlled and is listed on NYSE Euronext Paris. It develops immunotherapy products for the treatment of cancer and infectious diseases. www.transgene.fr Silliker is a privately-owned company, 86% controlled, based in Chicago (United States), encompassing a network of nearly 50 laboratories dedicated to improving food safety and nutrition. www.silliker.com Institut Mérieux employs nearly 10,000 people in the service of public health worldwide and generates net sales of over 1.4 billion Euros. *

	Start	1990-01-01 existent
	Group	Mérieux (Group)
	Industry	in vitro diagnostics (IVD)
	Industry 2	food analysis (food testing)

	Region	Lyon
	Country	France
	City	n. a. Lyon
		Address record changed: 2020-12-02

Basic data	Employees	G: 5,001 to 10,000 (2010-08-12)
	Currency	EUR
	Annual sales	1,400,000,000 (net sales (2009) 2009-12-31)

		* Document for ï¿½About Sectionï¿½:

		Record changed: 2020-12-04